Xiang Yue

Name: dblp XML data dump
Creator: Schloss Dagstuhl - Leibniz Center for Informatics
Published: 1993
License: https://creativecommons.org/publicdomain/zero/1.0/
Keywords: dblp, XML, computer science, scholarly publications, metadata

◀ ▶ joint publications with Yanlin Chen 0002

> Home > Persons > Xiang Yue

Publications

2018
[j4]
- view
  - electronic edition via DOI (open access)
  - details & citations
  authority control:
- export record
  dblp key:
  - journals/jbi/ZhangCLY18
- ask others
- share record
  persistent URL:
  - https://dblp.org/rec/journals/jbi/ZhangCLY18
Wen Zhang, Yanlin Chen, Dingfang Li, Xiang Yue:
Manifold regularized matrix factorization for drug-drug interaction prediction. J. Biomed. Informatics 88: 90-97 (2018)
2017
[j2]
- view
  - electronic edition via DOI (open access)
  - details & citations
  authority control:
- export record
  dblp key:
  - journals/bmcsb/ZhangYLCTZ17
- ask others
- share record
  persistent URL:
  - https://dblp.org/rec/journals/bmcsb/ZhangYLCTZ17
Wen Zhang, Xiang Yue, Feng Liu, Yanlin Chen, Shikui Tu, Xining Zhang:
A unified frame of predicting side effects of drugs by using linear neighborhood similarity. BMC Syst. Biol. 11(6): 23-34 (2017)
[c3]
- view
  authority control:
- export record
  dblp key:
  - conf/bibm/ZhangYCLLLL17
- ask others
- share record
  persistent URL:
  - https://dblp.org/rec/conf/bibm/ZhangYCLLLL17
Wen Zhang, Xiang Yue, Yanlin Chen, Weiran Lin, Bolin Li, Feng Liu, Xiaohong Li:
Predicting drug-disease associations based on the known association bipartite network. BIBM 2017: 503-509

manage site settings

To protect your privacy, all features that rely on external API calls from your browser are turned off by default. You need to opt-in for them to become active. All settings here will be stored as cookies with your web browser. For more information see our F.A.Q.